Mechanisms of disease: signal transduction in lung carcinogenesis - a comparison of smokers and never-smokers

被引:16
作者
Mountzios, Giannis [1 ]
Fouret, Pierre [3 ]
Soria, Jean-Charles [2 ]
机构
[1] Univ Athens, Alexandra Univ Hosp, Dept Clin Therapeut, Sch Med, GR-11528 Athens, Greece
[2] Univ Paris 11, Inst Gustave Roussy, Dept Med, Paris, France
[3] Univ Paris 11, Inst Gustave Roussy, Lab Translat Res, Paris, France
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 10期
关键词
downstream effectors; lung cancer; never-smokers; signaling pathways; smokers;
D O I
10.1038/ncponc1181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although smoking has been established as the most important cause of lung cancer, approximately 10% of patients with this malignancy have no history of smoking. The pathogenesis of tobacco-related lung carcinogenesis is becoming well characterized, but the molecular mechanisms of neoplastic transformation in never-smokers have not yet been adequately elucidated. Nevertheless, numerous recent studies have revealed a distinct biological process of malignant transformation with unique epidemiological and clinicopathological characteristics in never-smokers. The molecular pathways involved in the differential pattern of lung oncogenesis according to smoking status, however, remain fairly obscure. Researchers have studied several molecular pathways implicated in lung carcinogenesis in smokers and never-smokers, examining these processes at the genomic, epigenetic and proteomic level. The differential protein expression according to smoking status in critical signal transduction pathways has attracted scientific interest because of the possibilities of therapeutic intervention. In this Review we describe the best-characterized signaling pathways implicated in the transduction of proliferative signals and discuss the activity of these pathways in smokers and never-smokers.
引用
收藏
页码:610 / 618
页数:9
相关论文
共 80 条
[1]   Intracellular signal transduction pathway proteins as targets for cancer therapy [J].
Adjei, AA ;
Hidalgo, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5386-5403
[2]  
Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO
[3]  
2-H
[4]   Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells [J].
Akca, Hakan ;
Tani, Masachika ;
Hishida, Tomoyuki ;
Matsumoto, Shingo ;
Yokota, Jun .
LUNG CANCER, 2006, 54 (01) :25-33
[5]  
Akopyan G, 2006, INT J ONCOL, V29, P745
[6]   Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor [J].
Alvarez, JV ;
Greulich, H ;
Sellers, WR ;
Meyerson, M ;
Frank, DA .
CANCER RESEARCH, 2006, 66 (06) :3162-3168
[7]   Lung cancer rates in men and women with comparable histories of smoking [J].
Bain, C ;
Feskanich, D ;
Speizer, FE ;
Thun, M ;
Hertzmark, E ;
Rosner, BA ;
Colditz, GA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) :826-834
[8]   Treating cancer's kinase 'addiction' [J].
Baselga, J ;
Arribas, J .
NATURE MEDICINE, 2004, 10 (08) :786-787
[9]  
Blackhall FH, 2003, CLIN CANCER RES, V9, P2241
[10]   p38 MAPK in development and cancer [J].
Bradham, Cynthia ;
McClay, David R. .
CELL CYCLE, 2006, 5 (08) :824-828